Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

AbbVie Gains FDA Approval For Subcutaneous Induction Of SKYRIZI In Crohn's Disease

24 October 2026 · By · Wire by Fusion42

Published

24 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 24 October 2026 · Fusion42 review

AbbVie has received FDA approval for the subcutaneous induction use of SKYRIZI in treating Crohn's disease, expanding its administration options for patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You now have a new regulatory path cleared for patient-friendly Crohn's treatments. Regulatory clearance for subcutaneous SKYRIZI opens room to challenge traditional Crohn's therapies quickly.

◆ Coverage

2 sources · 24 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalbiotechcrohns-diseaseabbviedrug-innovation